BUZZ-Shanghai Henlius jumps most in 3-1/2 months on tumour drug trial approval** Shanghai Henlius Biotech 2696.HK stock surges 7.7% to HK$58.8, set for biggest one-day gain since Oct 8
** Stock hits highest level since Jan 23, snapping 7-session losing streak
** China's drug regulator approves clinical trial for antibody-drug conjugate HLX43 combined with monoclonal antibody HLX07 for advanced solid tumours, co says
** Company says it intends to commence the relevant clinical trials in mainland China when conditions are met
** YTD, stock up 2.1%, Hang Seng Biotech Index .HSBIO up 11.8%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments